<DOC>
	<DOCNO>NCT00109291</DOCNO>
	<brief_summary>To evaluate safety profile single intravenous ( IV ) dose level peginesatide participant chronic kidney disease ( CKD ) dialysis .</brief_summary>
	<brief_title>Safety Single Doses Peginesatide Patients With Chronic Kidney Disease</brief_title>
	<detailed_description>This Phase 2a , randomize , double-blind , placebo-controlled , sequential dose escalation study conduct single clinical center . The study design evaluate 6 treatment cohort 9 participant CKD dialysis first cohort 5 participant subsequent cohort . In treatment cohort , participant randomly assign receive either single dose peginesatide ( n=7 first cohort , n=4 subsequent cohort ) placebo ( n=2 first cohort , n=1 subsequent cohort ) . Participants follow minimum 28 day .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Hematinics</mesh_term>
	<criteria>1 . Participant inform investigational nature study give write , witness informed consent accordance institutional , local , national guideline ; 2 . Males females ≥ 18 ≤ 75 year age . Premenopausal female ( exception surgically sterile ) must negative pregnancy test screening ; sexually active must practice adequate form contraception least 2 week prior study start , must willing continue contraception least 4 week receive study drug ; 3 . Chronic kidney disease stage 3 4 ( glomerular filtration rate [ GFR ] 1560 milliliter per minute ( mL/min ) within 28 day prior administration study drug , ) require dialysis ; 4 . Two hemoglobin value ≥ 9 gram per deciliter ( g/dL ) ≤ 11 g/dL within 14 day prior administration study drug , one value draw within 7 day prior administration study drug ; 5 . One serum ferritin level ≥ 100 microgram per liter ( µg/L ) one transferrin saturation ≥ 20 % within 28 day prior administration study drug ; 6 . One serum folate level lower limit normal within 28 day prior administration study drug ; 7 . One vitamin B12 level lower limit normal within 28 day prior administration study drug ; 8 . Weight ≥ 45 kg within 28 day prior administration study drug ; 9 . One white blood cell count ≥ 3.0 x 10^9/L within 28 day prior administration study drug ; 10 . One platelet count ≥ 140 x 10^9/L ≤ 500 x 10^9/L within 28 day prior administration study drug . 1 . Prior treatment erythropoiesis stimulate agent ; 2 . History pure red cell aplasia ; 3 . Red blood cell transfusion within 3 month prior study drug administration ; 4 . Hemoglobinopathy ( e.g. , homozygous sicklecell disease , thalassemia type , etc . ) ; 5 . Hemolysis base medical judgment ; 6 . Chronic , uncontrolled , symptomatic inflammatory disease ( e.g. , rheumatoid arthritis , systemic lupus erythematosus , etc . ) ; 7 . C Reactive Protein ( CRP ) great 30 mg/L within 14 day prior administration study drug ; 8 . Significant infection within 4 week prior study drug administration , per Investigator 's clinical judgment ; 9 . Febrile illness within 7 day prior administration study drug ; 10 . Uncontrolled symptomatic secondary hyperparathyroidism ; 11 . Poorly control hypertension within 4 week prior study drug administration , per Investigator 's clinical judgment ( e.g . systolic ≥ 170mm Hg , diastolic ≥ 100 mm Hg repeat reading ) ; 12 . Epileptic seizure 6 month prior study drug administration ; 13 . Chronic congestive heart failure ( New York Heart Association Class IV ) ; 14 . High likelihood early withdrawal interruption study ( e.g. , myocardial infarction , severe unstable coronary artery disease , stroke , respiratory , autoimmune , neuropsychiatric , neurological abnormality , liver disease include active hepatitis B C , active HIV disease , clinically significant medical disease condition within past 6 month may , Investigator 's opinion , interfere assessment followup patient ) ; 15 . Malignancy ( except nonmelanoma skin cancer ) ; 16 . Life expectancy &lt; 12 month ; 17 . Anticipated elective surgery study period ; 18 . Previous exposure investigational agent within 4 month prior administration study drug plan receipt study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>anemia</keyword>
	<keyword>chronic kidney disease</keyword>
	<keyword>CKD</keyword>
	<keyword>chronic renal failure</keyword>
	<keyword>CRF</keyword>
	<keyword>dialysis</keyword>
	<keyword>erythropoietin</keyword>
	<keyword>EPO</keyword>
	<keyword>erythropoiesis stimulating agent</keyword>
	<keyword>ESA</keyword>
	<keyword>Hematide™</keyword>
	<keyword>hemoglobin</keyword>
	<keyword>Hb</keyword>
	<keyword>Hgb</keyword>
	<keyword>Omontys</keyword>
	<keyword>peginesatide</keyword>
	<keyword>red blood cell</keyword>
	<keyword>red blood cell production</keyword>
</DOC>